Acera Surgical, a spinout of Washington University in St Louis, has raised an initial $5.1m out of a targeted $10m.
Acera Surgical, a US-based bioscience spinout of Washington University in St Louis, has raised $5.1m from unnamed investors, according to a regulatory filing.
The company is targeting a $10m final close for the round.
Founded in 2013, Acera Surgical has developed an implantable nanomedical scaffold, called Cerafix, that can be used for soft tissue repair, and a protective wound cover called Restrata. The materials are broken down and assimilated back into the body.
The technology was co-invented by the spinout’s co-founder, president and chief scientist officer Matthew MacEwan, who completed a PhD in biomedical engineering at Washington University.
Acera previously closed a $600,000 funding round in 2013 led by Missouri Technology Corporation, with participation from two undisclosed backers.